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HLA allele.
The pool of CTL donors inherited HLA alleles in frequencies
similar to those in caucasian and black populations, with
certain alleles overrepresented. In 55% of the CTL lines, the ID
T-cell response (TCr) was restricted (restr.) by 3 HLA alleles:
A0201(25%), B0702(21%) and B 3501-11(9%); 45% of CTL lines
were restr. by other class-I alleles, and 17/123(14%) were
restr. by class-II alleles. Certain CMVpp65 15 mers contained
overlapping eps presented by both class-I and class-II, which
elicitedmore robust TCr. CTLs from all B0702+ donors (26/26)
were restr. by B0702. In comparison, CTLs from 30/39(77%)
A0201+ donors and 9/19 (47%) HLA B3501-11+ donors were
restr. by A0201 and B3501-11 respectively. Donors co-
inheriting A0201 and B 0702 (9/9) universally demonstrated
B0702 restr. ID TCr. In comparison, 11/12 (91.6%) donors co-
inheriting A0201 and B 4401-04 demonstrated HLA A0201
restr. CTLs. Strikingly, only 1/123 and 0/123 A1101+ and
A0301+ donors respectively demonstrated CTLs restr. by
these commonly inherited class eI alleles. This analysis thus
indicates an immunodominance hierarchy for CMVpp65 eps
and their presenting HLA alleles. In a series of 239 MUD, 137
MMUD, and 100 DUCB consecutive HSCT at MSKCC, we could
identify an immediately available CMVpp65 speciﬁc CTL line
matched with the patient at 2-3 alleles and restr. by a shared
HLA allele in this GMP-CTL bank in 86%, 89% and 80% cases
respectively. This CTL bank thus provides a clinical reagent
for the treatment of CMV infections in HSCT recipients. The
delineated immunodominance hierarchy for CMVpp65 may
also facilitate selection of an appropriately restr. CTL line for
treatment with predicted activity in the recipient. We can
also successfully generate CMV-CTLs against subdominant
CMVpp65 eps presented prevalent HLA alleles using a panel
of artiﬁcial antigen presenting cells (AAPCs). Expansion of
this bank with CTLs generated with AAPCs can broaden its
applicability to almost all HSCT recipients.180
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Lymphodepletion before adoptive cell transfer (ACT) can
enhance anti-tumor responses by increasing access to ho-
meostatic cytokines and by depressing the numbers of reg-
ulatory cells. However, the lymphodepleted recipient is at
risk for morbidity and mortality from pathogens. Indeed,
opportunistic invasive fungal infection (IFI) by Aspergillus sp.
results in a 60 to 85% in patients undergoing hematopoietic
stem-cell transplantation. Antifungal agents such as poly-
enes, triazoles, and echinocandins can be rendered ineffec-
tive due to shifts in fungal epidemiology, emergence of drug
resistant strains, and attendant toxicities in the recipients.
Thus, other strategies are being developed that target fungi.
Clinical-grade T cells genetically modiﬁed to express
chimeric antigen receptors (CARs) have been successfully
used to redirect speciﬁcity to target tumor-associated anti-
gens. We and others have infused CD19-speciﬁc T cells inpatients undergoing HSCT for investigational treatment of B-
cell malignancies. This provides a platform to expand the role
of adoptive immunotherapy to also target IFI.We adapted the
pattern-recognition receptor Dectin-1 to activate T cells via
chimeric CD28 and CD3-z (designated D-CAR) upon binding
with carbohydrate cell wall in Aspergillus germlings. The D-
CAR+ T cells exhibited speciﬁcity for b-1,3-gucan and
inhibited hyphal growth of Aspergillus. The D-CAR was then
expressed with our CD19-speciﬁc CAR (designated
CD19RCD28) which is currently used in clinical trials. Our
existing manufacturing platform was readily adapted to
electro-transfer plasmids from the Sleeping Beauty (SB) sys-
tem. Clinical-grade CD19-speciﬁc CAR+ T cells are produced
after introducing two DNA plasmids coding for transposon
(CD19RCD28) and transposase (SB11). The synchronous
electro-transfer of a third SB-derived DNA plasmid coding for
D-CAR resulted in CD19RCD28+D-CAR+ T cells. The resultant
genetically modiﬁed T cells can target both CD19+ malignant
B cells and Aspergillus. Generating CD19-speciﬁc T cells with
multiple speciﬁcities will enable introduced fungal immu-
nity to be long-lived and provides a foundation for engi-
neering an immune response with that can target multiple
antigens, such as to prevent the emergence of antigen-
escape variants.181
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Adoptive transfer of ag speciﬁc T-cells can effectively eradi-
cate viral infections and tumors. T-cells can be targeted to
speciﬁc ags expressed on tumor cells by genetic modiﬁcation
to express chimeric ag receptors (CARs); which are fusion
proteins incorporating an ag recognition moiety (ab) and T-
cell activation domains. Human T-cells genetically modiﬁed
to express a CD19-targeted CAR have been demonstrated to
successfully eradicate CD19+ B cell malignancies in patients
with refractory disease. The CARs developed thus far have
been directed against native cell-surface antigens, such as
CD19, that are recognized through antibody-derived anti-
gen-binding motifs, independent of antigen processing or
MHC-restricted presentation. However, tumor associated
intracellular self ags such as WT-1 require processing
following which antigenic epitopes are presented on the
tumor cell surface in complex with HLA class-I or class-II. A
strategy for targeting T-cells to speciﬁc peptide epitopes of
such self ags expressed on tumor cells involves genetically
introducing TCR mimic CARs containing a scFv ab directed
against the speciﬁc peptide-MHC complexes. CARs contain-
ing a Fab directed against an HLA-A0201-NY-ESO-1 epitope
have been generated, but functional data is lacking. We
generated a TCR-like CAR containing a scFv speciﬁc for an
HLA/peptide complex; the WT-1 RMFPNAPYL peptide pre-
sented by HLA-A0201 (A2-RMF CAR). The original A2-RMF
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binding afﬁnity (Kd¼ 2.3 x 10-7 M). T-cells were transduced
to express the A2-RMF CAR using MSCV retroviral vector.
However, CAR transduced T-cells bearing the low afﬁnity A2-
RMF ScFv did not demonstrate any binding to the A2-RMF
tetramers, and did not demonstrate any in-vitro cytotoxic
activity against A2+/WT-1+ tumor cell targets. We subse-
quently developed an afﬁnity matured ScFv (Kd¼ 3.08 x 10-9
M) to determine if ScFv binding afﬁnity correlated with
functional activity. T-cells transduced to express CARs
bearing the afﬁnity matured A2-RMF ScFv demonstrated
strong binding to the A2-RMF tetramer in all transduced
cells. The afﬁnity matured A2-RMF CAR modiﬁed T-cells
were able to kill A2+/WT-1+ solid tumor or B cell leukemia
cell lines (29% -40% speciﬁc lysis) at E:T ratios of 50:1 and
20:1, in comparison to 1-4% speciﬁc lysis for HLA A2-/WT-1+
or A2+/WT-1- control tumor cell lines. These data demon-
strate that a TCR-mimic CAR bearing scFv against an A2-RMF
complex, can bind to A2-RMF tetramers and effectively lyse
tumor cell targets co-expressing HLA A2 and WT1 in an HLA
restricted and antigen speciﬁc manner. The results also
suggest that the binding afﬁnity of the antibody is important
for effective functional activity of CAR modiﬁed T-cells
directed against epitopes of self tumor associated antigens.182
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Background: Development of novel (immune) therapies is
of utmost importance to improve survival in relapsed pedi-
atric-AML (acute myeloid leukemia). We aim to develop a
powerful and safe therapy consisting of two potentially
synergistic components: Cord Blood (CB) HSCT and vacci-
nation with CB-derived Wilms Tumor-1 (WT1) mRNA-elec-
troporated dendritic cells (DCs).
Materials & Methods: After isolation, the CD34+ CB stem
cells were cultured using a two-step protocol. First, they
were expanded using a combination of (growth) factors
(Flt3L, SCF, IL-3 and IL-6). Next, the cells were differentiated
towards DCs for one week using medium containing Flt3L,
SCF, GM-CSF, IL-4 and human serum followed by a CYTOMIX
(IL-1beta, IL-6, TNF-alpha and PGE2)-induced maturation for
the last 24 hours. Finally, the CB-DC culture was electro-
porated with WT1-mRNA and their phenotype (cell surface
markers) and function (migration and antigen presentation)
were assessed.
Results: Using the two-step protocol a total cell expansion of
300-500 fold was achieved. Based on surface marker
expression, different DC subsets could be distinguished in
our CB-DC cultures. Since no differences in antigen presen-
tation capacity between the DC subsets were detected, the
whole CB-DC culture was used in all phenotypic and func-
tional assays. The maturation using CYTOMIX induced
upregulation of costimulatory molecules (CD80, CD83 and
CD86) and the chemokine receptor CCR7 on the CB-DCs.
These matured CB-DCs showed enhanced CCR7-dependent
migration towards CCL21 in a trans-well migration assay. The
presentation of WT1 peptides by the CB-DC culture, maturedusing CYTOMIX and electroporated with WT1 mRNA, was
conﬁrmed by the stimulation of T cells expressing a recom-
binant WT-1 peptide speciﬁc TCR. Furthermore, this same
CB-DC culture was able to induce expansion of the WT-1
speciﬁc T cells from their autologous pool of nave T cells in
cord blood. Conclusion: We have developed and tested an in
vitro system for culturing large amounts of DCs from the
CD34+ CB stem cells. Both the phenotypic and functional
data support the use of the whole CB-DC culture as vaccine.
We are currently translating our preclinical protocol to GMP
production of a clinical grade vaccine.183
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Autologous HPC transplants require the collection of sufﬁ-
cient HPCs to ensure engraftment. Inefﬁcient HPC harvests
lead to an over utilization of cytokines (GSCF, Plerixafor),
impose a limitation on storage space and lead to a waste of
resources, material and human. We report the use of an al-
gorithm based on a previously demonstrated positive linear
correlation between peripheral blood HPC dose and the
product HPC dose, to improve the efﬁciency of HPC collection
in patients undergoing autologous HPC harvests.
Methods: HPC collections on 62 consecutive patients were
analyzed. All patients received GCSF priming. Peripheral
blood CD34 (PHPC) counts were enumerated in 31 cases after
the adoption of the predictive algorithm (Cohort 2), and not
in the preceding 31 cases (Cohort 1). PHPC counts were
performed from day 4 of GCSF administration. Product CD34
count was expressed per kg of recipient weight. In Cohort 2
the predetermined algorithm was used to decide on the use
of Plerixafor and timing of collection. Based on peripheral
blood CD 34 counts (cells/mL) patients in Cohort 2 were
grouped into three categories (A:< 7, B:7-10,C:>10). Group A
received Plerixafor prior to collection. For group B the deci-
sion to use Plerixafor was deferred to the physician. Group C
did not receive Plerixafor prior to collection. Further dosing
of Plerixafor was determined by the product CD34 count. The
use of Plerixafor in the two cohorts was assessed retro-
spectively. The association between testing the PHPC count
and the use of Plerixafor was performed using the Chi Square
test. The Wilcoxon Rank Sum test was used to compare the
median number of collections between the two groups. The
proportional difference in patients receiving Plerixafor be-
tween the 2 cohorts was assessed using the Fisher Exact Test.
Results: In Cohort 1 (21 Myeloma and 10 Lymphoma) 80
collections were performed. In Cohort 2 (19 myeloma, 12
Lymphoma) 75 collections were performed. The target
collection was achieved in all patients. Forty three doses of
Plerixafor were administered in 14 patients in Cohort 1, and
21 doses in 6 patients in Cohort 2. The average daily charge
per collection with Plerixafor was $37728.9 and $11406,
without. There was a signiﬁcant association between the use
of a predictive PHPC count and following the algorithm, and
the use of Plerixafor (p ¼ 0.0011). The proportion of collec-
tions preceded by Plerixafor was higher when a PHPC count
was not performed (54% vs 28%, p¼ 0.0009). Proportionately,
